Some studies have shown that IL-6 plasma concentrations may be positively correlated with systemic insulin resistance, IL-6 liver expression, hepatic inflammation, and fibrosis degree in NAFLD patients (39–41). This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.